Wells Fargo & Company MN Purchases 11,498 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Wells Fargo & Company MN lifted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 37.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,117 shares of the company’s stock after acquiring an additional 11,498 shares during the quarter. Wells Fargo & Company MN’s holdings in Syndax Pharmaceuticals were worth $557,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SNDX. Barclays PLC raised its holdings in Syndax Pharmaceuticals by 143.4% during the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock worth $3,612,000 after purchasing an additional 110,535 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock worth $34,948,000 after buying an additional 208,043 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Syndax Pharmaceuticals by 343.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock worth $27,292,000 after buying an additional 1,598,428 shares during the last quarter. Inspire Investing LLC lifted its holdings in Syndax Pharmaceuticals by 44.5% in the fourth quarter. Inspire Investing LLC now owns 30,792 shares of the company’s stock valued at $407,000 after buying an additional 9,484 shares during the period. Finally, KBC Group NV lifted its holdings in Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after buying an additional 3,559 shares during the period.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $13.73 on Friday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -3.78 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $25.07. The stock’s 50 day moving average price is $12.89 and its two-hundred day moving average price is $14.71.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $86.32 million. On average, equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Scotiabank dropped their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Citigroup reduced their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Insider Activity at Syndax Pharmaceuticals

In other news, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares of the company’s stock, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Keith A. Goldan sold 3,777 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,683 shares of company stock valued at $336,087. Insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).